Podcast: Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage
Phase I Trials For OCU-400 Set For Q1 2022
Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.
